The Japanese company alleges the earlier Ranbaxy promoters withheld crucial information when they sold the company in 2008.
The company said it is launching the product immediately
The tablets are bio equivalent generic version of GlaxoSmithKline's Requip XL tablets
Hyderabad, Mar 28 (PTI) Dr Reddy's Laboratories Limited has launched Levocetirizine tablets (5mg), a bio-equivalent generic version of Xyzal tablets in the USA market, the company said on Monday.
Pharmaceutical and biotechnology major, Wockhardt has received final approval from the United States Food & Drug Administration for marketing the cardiac drug.
The Ahmedabad-based Claris Lifesciences has received the United States Food & Drug Administration clearance for its sterile injectable manufacturing facility near Ahmedabad.
The first two coaches that rolled out from the Railway Coach Factory in Kapurthala also have fixtures coated with titanium dioxide and the provision for plasma air equipment in AC ducts to sterilise interiors using ionised air. Railway Minister Piyush Goyal also indicated that the new coaches could be the new normal.
It is the generic version of Teva Women's Health's Seasonale tablets
Wockhardt Ltd said on Thursday it has received approval from USFDA for marketing antibiotic, Clarithromycin tablets, in the US market.
.jpg)
The company has launched the Decitabine for injection in the strength of 50 mg in the US market following approval by the United States Food & Drug Administration of Dr Reddy's abbreviated new drug applications, it said in a statement.
Wockhardt has received United States Food & Drug Administration approval to market Zonisamide capsules.
Cipla has got tentative approval from the USFDA for its abbreviated new drug application for anti-HIV/AIDS drug Slamivudine.
The Sensex ended lower on unfavourable cues.
Dilip Shanghvi has never tried to be everything to everybody.
Ranbaxy did its maiden public issue in 1973.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances